New Hope for Women's Health:
Aditxt and Evofem Team Up to Launch Breakthrough Endometriosis Diagnostic

Aditxt and Evofem Biosciences have partnered to commercialize a groundbreaking blood-based diagnostic test for endometriosis, set to launch in the US by mid-2025. The collaboration focuses on developing a strategic marketing and commercialization plan for Pearsanta’s Mitomic Endometriosis Test (MET), which identifies a unique mitochondrial DNA deletion, offering a non-invasive alternative for diagnosing this often overlooked condition.

Evofem’s CEO, Saundra Pelletier, highlighted their strong ties with OB/GYNs and healthcare providers as key to the test’s successful launch. The companies also plan to explore expanding their women’s health portfolio with additional diagnostics, including early detection tests for ovarian cancer.